Docetaxel use associated with significant reduction in prostate cancer death

Written By : Isra Zaman

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2023-11-04 03:45 GMT | Update On 2023-11-04 09:27 GMT

In a new study, investigators from Brigham and Women's Hospital, a meta-analysis of five prospective randomized clinical trials (RCTs) found that adding docetaxel to standard-of-care (SOC) treatment was associated with a 70% reduction in death from prostate cancer-specific mortality (PCSM). The study was published in JAMA Network Open.

Investigators performed a meta-analysis of the RCTs evaluating SOC treatment with radiotherapy and androgen deprivation therapy or with radical prostatectomy versus SOC plus docetaxel. The final study cohort of 2,184 patients included 145 eligible patients (6.6%) across four eligible RCTs.

"Of these 145 patients, 139 had excellent performance status [PS] and were the main focus of the study. An excellent PS identifies patients who can tolerate the full course of chemotherapy and therefore benefit if the treatment proves effective," says Anthony Victor D'Amico, senior author of the study.

Among these 139 patients, SOC plus docetaxel was associated with a significant 70% reduction in PCSM and nearly halved all-cause mortality. Remarkably, this treatment regiment dropped the 10-year PCSM rate from nearly 40% to less than 10%, leading to a 10-year overall survival of 80% as compared to 60%.

Reference: Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels

Full View

Article Source : JAMA Network Open

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Isra Zaman

Isra Zaman is a Life Science graduate from Daulat Ram College, Delhi University, and a postgraduate in Biotechnology from Amity University. She has a flair for writing, and her roles at Medicaldialogues include that of a Sr. content writer and a medical correspondent. Her news pieces cover recent discoveries and updates from the health and medicine sector. She can be reached at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Docetaxel use associated with significant reduction in prostate cancer death

Similar News

New Liquid Biopsy May Detect HPV-Related Cancers 10 Years Before Symptoms: Study Finds

How Smoking Fuels Pancreatic Cancer Growth and Worsens Outcomes: Study Finds Out

New Urine Test May Detect Prostate Cancer with 91 Percent Accuracy: Study

India Sees Higher Cancer Incidence in Women but Greater Mortality in Men: ICMR Study

This Diet May Cut Risk of Cancer and Heart Disease Multimorbidity: Study Suggests

Real-World Case: Managing Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Akhil Kapoor

One Workout May Trigger Tumor-Suppressing Proteins in Cancer Survivors: Study Shows

New Web-Based Tool Aims to Cut Lung Cancer Deaths with Tailored Strategies, Reveals Research